Celgene Corporation (CELG)

93.92
NASDAQ
Prev Close 93.10
Day Low/High 92.85 / 94.15
52 Wk Low/High 58.59 / 95.44
Exchange NASDAQ
Shares Outstanding 702.45B
Market Cap 65.40B
Div & Yield N.A. (N.A)

Latest News

Bristol-Myers Tops Q1 Earnings Estimate After Winning Celgene Takeover Approval

Bristol-Myers Tops Q1 Earnings Estimate After Winning Celgene Takeover Approval

Bristol-Myers Squibb posted stronger than-expected first quarter earnings Thursday, and boosted one of its key profit forecast, after seeing off an activist challenge to its $74 billion takeover of cancer specialist Celgene earlier this month.

Stocks Edge Lower as Growth Concerns Resurface, Offsetting Solid US Earnings

Stocks Edge Lower as Growth Concerns Resurface, Offsetting Solid US Earnings

Global stocks pared gains Thursday, as weakening data and dovish central bank actions added to concerns over the pace of world growth and offset the bullish tenor from last night's after-the-bell earnings on Wall Street.

Bristol-Myers Squibb Company Announces Commencement Of Exchange Offers And Consent Solicitations For Celgene Notes

Bristol-Myers Squibb Company Announces Commencement Of Exchange Offers And Consent Solicitations For Celgene Notes

Bristol-Myers Squibb Company (NYSE:BMY) ("Bristol-Myers Squibb) announced today the commencement, in connection with its previously announced acquisition of Celgene Corporation (NASDAQ:CELG) ("Celgene") , of an exchange offer for any and all outstanding...

Bullish Start to Earnings: Cramer's 'Mad Money' Recap (Friday 4/12/19)

Bullish Start to Earnings: Cramer's 'Mad Money' Recap (Friday 4/12/19)

Jim Cramer says this positive start will be hard to sustain this earnings season. He's got your game plan for next week.

Bristol-Myers Squibb Shareholders Approve Celgene Tie-Up

Bristol-Myers Squibb Shareholders Approve Celgene Tie-Up

Three quarters of Bristol-Myers Squibb shareholders vote to approve the deal with Celgene, paving the way for the largest pharmaceutical takeover in history.

Celgene Stockholders Approve Proposed Acquisition By Bristol-Myers Squibb

Celgene Stockholders Approve Proposed Acquisition By Bristol-Myers Squibb

Celgene Corporation (NASDAQ: CELG) today announced that its stockholders have voted to approve the company's proposed combination with Bristol-Myers Squibb Company (NYSE: BMY).

Celgene Corporation And Acceleron Pharma Announce Submission Of Luspatercept Biologics License Application To U.S. FDA

Celgene Corporation And Acceleron Pharma Announce Submission Of Luspatercept Biologics License Application To U.S. FDA

Celgene Corporation (NASDAQ: CELG) and Acceleron Pharma Inc. (NASDAQ: XLRN) today announced that Celgene has submitted a Biologics License Application (BLA) for luspatercept, an erythroid maturation agent, for the treatment of adult patients with very low...

Predicting the Future: Cramer's 'Mad Money' Recap (Monday 4/1/19)

Predicting the Future: Cramer's 'Mad Money' Recap (Monday 4/1/19)

How can stocks rally with money coming out so swiftly? Jim Cramer says to take a look at the 5 best performing stocks in the Dow for the first quarter.

Williams-Sonoma, Fortive, Western Digital: 'Mad Money' Lightning Round

Williams-Sonoma, Fortive, Western Digital: 'Mad Money' Lightning Round

Jim Cramer takes a look at Williams-Sonoma, Fortive, Western Digital, Goodyear Tire & Rubber, Celgene, Welltower, Box and Twitter.

Keep Your Eye on the Oncology Sector Among Biotech Stocks

Keep Your Eye on the Oncology Sector Among Biotech Stocks

The myriad names in oncology have been the hottest area for acquisitions along with gene therapy.

Bristol-Myers Gets ISS Support for Celgene Takeover; Starboard Drops Opposition

Bristol-Myers Gets ISS Support for Celgene Takeover; Starboard Drops Opposition

Celgene surges Friday after an influential shareholder advisory group recommend investors vote in favor of the cancer drug specialist's takeover by Bristol-Myers Squibb Co. while a key activist dropped its opposition to the $74 billion deal.

Celgene Settles U.S. REVLIMID® Patent Litigation With Alvogen

Celgene Settles U.S. REVLIMID® Patent Litigation With Alvogen

Celgene Corporation (NASDAQ:CELG) and Lotus Pharmaceutical Co., Ltd.

Celgene Receives CHMP Positive Opinions For Both REVLIMID® (lenalidomide) And IMNOVID® (pomalidomide)-Based Triplet Combination Regimens For Patients With Multiple Myeloma

Celgene Receives CHMP Positive Opinions For Both REVLIMID® (lenalidomide) And IMNOVID® (pomalidomide)-Based Triplet Combination Regimens For Patients With Multiple Myeloma

Celgene Corporation (NASDAQ:CELG), today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted positive opinions for two triplet regimens based on Celgene's proprietary IMiD ® medications,...

Stock Picking Comeback: Cramer's 'Mad Money' Recap (Thursday 3/28/19)

Stock Picking Comeback: Cramer's 'Mad Money' Recap (Thursday 3/28/19)

Lots of IPOs and innovation will reward investors who do their homework, Jim Cramer says.

Future Brightens for 2 Small Biotech Stocks

Future Brightens for 2 Small Biotech Stocks

The biotech sector isn't for the faint of heart, but these two companies issued promising news this week.

Bristol-Myers Gets FTC Request for More Information on $74 Billion Celgene Deal

Bristol-Myers Gets FTC Request for More Information on $74 Billion Celgene Deal

Bristol-Myers Squibb says Tuesday the Federal Trade Commission has requested information related to its planned $74 billion takeover of cancer drug company Celgene.

Bristol-Myers Squibb, Xilinx, Nieslen: 'Mad Money' Lightning Round

Bristol-Myers Squibb, Xilinx, Nieslen: 'Mad Money' Lightning Round

Jim Cramer takes a look at Bristol-Myers Squibb, Xilinx, Nieslen, Realty Income, W&T Offshore and more.

Celgene Submits Application To FDA For Ozanimod For The Treatment Of Relapsing Forms Of Multiple Sclerosis

Celgene Submits Application To FDA For Ozanimod For The Treatment Of Relapsing Forms Of Multiple Sclerosis

Celgene Corporation (NASDAQ:CELG) today announced that the Company has submitted a New Drug Application to the U.

Bristol-Myers Squibb Board Of Directors Sends Letter To Shareholders Highlighting The Compelling Strategic And Financial Rationale Of The Celgene Transaction; Company Provides Additional Investor Materials

Bristol-Myers Squibb Board Of Directors Sends Letter To Shareholders Highlighting The Compelling Strategic And Financial Rationale Of The Celgene Transaction; Company Provides Additional Investor Materials

Bristol-Myers Squibb Company's (NYSE:BMY) Board of Directors today sent an open letter to the Company's shareholders regarding the previously announced definitive merger agreement with Celgene Corporation (NASDAQ:CELG).

Bristol-Myers Pushes Celgene Deal, Starboard Hits Back, in $74B Takeover Spat

Bristol-Myers Pushes Celgene Deal, Starboard Hits Back, in $74B Takeover Spat

Bristol-Myers Squibb trades blows with activist investor Starboard Value Tuesday as the pair issues competing presentations linked to the pharmaceutical group's planned $74 billion takeover of cancer drug specialist Celgene.

Why Shareholders Should Vote for Bristol-Myers Celgene Deal: Jim Cramer

Why Shareholders Should Vote for Bristol-Myers Celgene Deal: Jim Cramer

Jim Cramer thinks that Bristol-Myer's deal with Celgene is a positive thing, despite Starboard's resistance.

Jim Cramer: Tilray's Earnings, Bristol-Myers and Celgene and Elon Musk

Jim Cramer: Tilray's Earnings, Bristol-Myers and Celgene and Elon Musk

Bristol-Myers, Tilray, and Elon Musk are some of the top headlines in business news Tuesday. Here's what Jim Cramer's watching.

Jim Cramer Breaks Down Tilray Earnings, Elon Musk's Twitter and Bristol-Myers

Jim Cramer Breaks Down Tilray Earnings, Elon Musk's Twitter and Bristol-Myers

Here's what you need to know about Tilray's earnings, Elon Musk's fight with the SEC and Bristol-Myers fight with Starboard over Celgene. Jim Cramer talks the markets

Celgene Provides Update On ABRAXANE® Combination Therapy In The Treatment Of Metastatic Triple-Negative Breast Cancer And Pancreatic Cancer

Celgene Provides Update On ABRAXANE® Combination Therapy In The Treatment Of Metastatic Triple-Negative Breast Cancer And Pancreatic Cancer

Celgene Corporation (NASDAQ: CELG) today announced two updates for ABRAXANE ® (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) in the treatment of metastatic triple-negative breast cancer and early stage pancreatic cancer.

Celgene Submits Application To EMA For Ozanimod For The Treatment Of Relapsing-Remitting Multiple Sclerosis

Celgene Submits Application To EMA For Ozanimod For The Treatment Of Relapsing-Remitting Multiple Sclerosis

Celgene Corporation (NASDAQ:CELG) today announced that the Company has submitted a Marketing Authorization Application to the European Medicines Agency (EMA) for ozanimod for the treatment of adults with relapsing-remitting multiple sclerosis (RRMS).

I Like the Long Side of Bristol-Myers Squibb

I Like the Long Side of Bristol-Myers Squibb

Let's see what the charts and indicators look like.

Fear of Big Sellers: Cramer's 'Mad Money' Recap (Wed. 3/6/19)

Fear of Big Sellers: Cramer's 'Mad Money' Recap (Wed. 3/6/19)

Jim Cramer says investors need to consider the bear the motivation, and they need to consider the big sellers they'll have to outrun.

The Real Money Post Industrial Average Gains More Ground in February

The Real Money Post Industrial Average Gains More Ground in February

However, the RMPIA did not see as much improvement last month as some other market indices.

TheStreet Quant Rating: C+ (Hold)